Vaccine, IFNalpha Kinoid, Seen to Lower Disease Activity and Steroid Use in Phase 2b Trial
Treatment with the investigational vaccine IFN-alpha Kinoid increased the number of systemic lupus erythematosus (SLE) patients achieving low disease activity, lessened their use of corticosteroids, and was well-tolerated, according to full results of a Phase 2b trial. The findings, “IFN Kinoid in Systemic Lupus Erythematosus (SLE):…